|
(Plastemart) -- Hubei Biocause
Pharmaceutical plans to invest 301.96 mln yuan in propylene production, which uses the process of
catalytic cracking of C4 olefin.
About 200.02 mln yuan will be earmarked for construction costs and 101.94
mln yuan for working capital. Capacities at the plant will comprise 21,800 tons
of propylene, 10,000 tons of propane and 120,000 tons of liquefied natural
gas.
mrcplast.com
|
